Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

Takeda’s Revestive becomes first approved drug in Europe for short bowel syndrome

Can reduce dependency on intravenous feeding

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

- PMLiVE

COPD-asthma cases set to grow in Europe as people live longer

Study also highlights the respiratory burden the elderly will face

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

- PMLiVE

European Commission wants tougher anti-smoking measures to halt spread of chronic diseases

Large number of young smokers will lead to further problems says EC's Martin Seychell at ERS congress

EMA grants accelerated assessment to Ariad’s leukaemia drug

Could cut months off approval decision for ponatinib

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

Novartis day

Novartis signs cancer immunotherapy deal with Penn

R&D alliance with the University of Pennsylvania will focus on novel T-cell immunotherapies

- PMLiVE

Almirall strikes UK commercial partnership with Quintiles

Agreement will focus on the promotion of Almirall's respiratory portfolio in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links